Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Operating Leases (2022 - 2025)

Ovid Therapeutics' Operating Leases history spans 4 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 10.68% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, down 10.68%, while the annual FY2025 figure was $12.0 million, 10.68% down from the prior year.
  • Operating Leases reached $12.0 million in Q4 2025 per OVID's latest filing, down from $12.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $16.2 million in Q3 2022 to a low of $12.0 million in Q4 2025.
  • Average Operating Leases over 4 years is $14.4 million, with a median of $14.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: decreased 1.09% in 2023, then dropped 10.68% in 2025.
  • A 4-year view of Operating Leases shows it stood at $16.0 million in 2022, then dropped by 7.78% to $14.8 million in 2023, then dropped by 9.06% to $13.4 million in 2024, then fell by 10.68% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Operating Leases are $12.0 million (Q4 2025), $12.4 million (Q3 2025), and $12.7 million (Q2 2025).